U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07540533) titled 'A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer' on Dec. 30, 2025.
Brief Summary: To evaluate the efficacy and safety of toripalimab in combination with investigator-selected chemotherapy in patients with recurrent or metastatic HER2-negative breast cancer who have failed prior systemic therapy.
Study Start Date: Jan. 20
Study Type: INTERVENTIONAL
Condition:
Advanced Breast Cancer
Intervention:
DRUG: Toripalimab
Toripalimab
DRUG: TPC
Treatment of Physician's Choice
Recruitment Status: RECRUITING
Sponsor: Henan Cancer Hospital
Information ...